亚洲制服欧美另类-午夜激情av电影-日本高清中文字幕一区二区三区-中国欧美日韩一区二区三区-欧洲亚洲日本韩国-成人欧美激情一区二区-亚洲偷偷自拍高清

掃碼關(guān)注公眾號(hào)           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  關(guān)于我們  聯(lián)系我們
性xxxxbbbb免费播放视频,成人日韩熟女高清视频一区,亚洲一级毛片免费观看
首頁(yè) > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Phospho-PPAR Gamma (ser273) Rabbit pAb (bs-4888R)  
訂購(gòu)熱線:400-901-9800
訂購(gòu)郵箱:sales@bioss.com.cn
訂購(gòu)QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價(jià)

產(chǎn)品編號(hào) bs-4888R
英文名稱 Phospho-PPAR Gamma (ser273) Rabbit pAb
中文名稱 磷酸化過(guò)氧化酶活化增生受體γ抗體
別    名 phospho-PPAR gamma(ser273); P-PPAR gamma(phospho-ser273); GLM1; CIMT1; NR1C3; PPARG; PPARG1; PPARG2; PPARG5; PPARgamma; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; Peroxisome pro  
Specific References  (40)     |     bs-4888R has been referenced in 40 publications.
[IF=38.104] Zhang Yudian. et al. 3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPARγ Ser273 phosphorylation in type 2 diabetic mice. SIGNAL TRANSDUCT TAR. 2023 May;8(1):1-10  WB ;  Mouse.  
[IF=12.067] Yang, Nanfei. et al. Blockage of PPARγ T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions. CELL DEATH DIFFER. 2022 Nov;:1-13  WB ;  Mouse.  
[IF=7.658] Lei Ma. et al. Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARγ-modulating ligand with good therapeutic index: Structure-based screening and biological validation. Pharmacol Res. 2021 Nov;173:105860  WB ;  Mouse.  
[IF=7.422] Dan Wu. et al. A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice. Mol Metab. 2021 Oct;:101363  WB ;  Mouse.  
[IF=7.419] Fangyuan Chen. et al. Identification of a novel PPARγ modulator with good anti-diabetic therapeutic index via structure-based screening, optimization and biological validation. BIOMED PHARMACOTHER. 2022 Oct;154:113653  WB ;  Mouse.  
[IF=7.199] Zhang C et al. Osteoprotegerin Promotes Liver Steatosis by Targeting the ERK-PPARγ-CD36 Pathway. Diabetes. 2019 Jul 10. pii: db181055.  WB ;  Mouse.  
[IF=7.103] Hou et al. CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss. (2018) Genes.Dis. 5:290-299  WB ;  Mouse.  
[IF=6.133] Huan Y et al. A novel specific PPARγ modulator YR4‐42 ameliorates hyperglycemia and dyslipidemia and hepatic steatosis in diet‐induced obese mice. Diabetes Obes Metab. 2019 Jul 31.  WB ;  Mouse.  
[IF=6.064] Maiara Ferreira Terra. et al. Obesity-Linked PPARγ Ser273 Phosphorylation Promotes Beneficial Effects on the Liver, despite Reduced Insulin Sensitivity in Mice. BIOMOLECULES. 2023 Apr;13(4):632  WB ;  Mouse.  
[IF=5.58] Agrawal, S., et al. "Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome." Scientific Reports 6 (2016): 24392.  IHC-P ;  Rat.  
[IF=5.486] Jian Yu. et al. Selective PPARγ modulator Diosmin improves insulin sensitivity and promotes browning of white fat. J BIOL CHEM. 2023 Feb;:103059  IP ;  Mouse.  
[IF=5.458] Claire Bryant. et al. Selective Modulator of Nuclear Receptor PPARγ with Reduced Adipogenic Potential Ameliorates Experimental Nephrotic Syndrome. Iscience. 2022 Feb;:104001  WB ;  Rat.  
[IF=5.307] Junyuan Tang. et al. Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPARγ-modulating ligand. BIOORG CHEM. 2022 Oct;:106191  WB ;  Mouse.  
[IF=5.195] Yu Wang. et al. An integrated study of Shenling Baizhu San against hyperuricemia: Efficacy evaluation, core target identification and active component discovery. J ETHNOPHARMACOL. 2022 Sep;295:115450  WB ;  Quail.  
[IF=5.116] Pengyu Hong. et al. Therapeutic potential of small extracellular vesicles derived from lipoma tissue in adipose tissue regeneration—an in vitro and in vivo study. Stem Cell Res Ther. 2021 Dec;12(1):1-13  IHC ;  Human.  
[IF=5.08] Liu, Chang, et al. "Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis." Scientific Reports 5 (2015).  WB ;  Mouse.  
[IF=5.059] Stephanie Kimet al. Triphenyl phosphate is a selective PPARγ modulator that does not induce brite adipogenesis in vitro and in vivo. Arch Toxicol . 2020 Sep;94(9):3087-3103.  WB ;  mouse.  
[IF=4.966] Ye Zhanget al. Thymopentin improves the survival of septic mice by promoting the production of 15‐deoxy‐prostaglandin J2 and activating the PPARγ signaling pathway. FASEB J . 2020 Sep;34(9):11772-11785.  WB ;  mouse.  
[IF=4.5] Liu, Lei, et al. "Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down‐regulation of phosphorylation of PPARγ in 3T3‐L1 cells." Journal of Cellular and Molecular Medicine (2017).  WB ;  Mouse.  
[IF=4.26] Alla, Joshua Abd, et al. "Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice." Journal of Biological Chemistry 291.6 (2016): 2583-2600.  WB ;  Mouse.  
[IF=4.26] Maganti, Aarthi V., et al. "Peroxisome Proliferator-Activated Receptor-γ Activation Augments the β Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-Obese Diabetic Mice."Journal of Biological Chemistry (2016): jbc-M116.  WB ;  Mouse.  
[IF=4.26] Stechschulte, Lance A., et al. "Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ and RUNX2." Journal of Biological Chemistry (2016).  WB ;  Mouse.  
[IF=4.171] Yingying Tian. et al. Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPARα/γ in mice. Food Funct. 2020 Sep;11(9):8248-8258  WB ;  Mouse.  
[IF=3.86] Liu, Lei, et al. "Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats." Molecular and Cellular Endocrinology (2016).  WB ;  Rat.  
[IF=3.73] Kolli, Vipula, et al. "Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass." PLOS ONE 9.5 (2014): e96323.  WB ;  Mouse.  
[IF=3.698] Yaru Guo. et al. Pioglitazone Attenuates Ischemic Stroke Aggravation By Blocking PPARγ Reduction and Inhibiting Chronic Inflammation in Diabetic Mice. EUR J NEUROSCI. 2022 Aug;:  WB ;  Mouse.  
[IF=3.514] Li B et al. Resistin up-regulates LPL expression through the PPARγ-dependent PI3K/AKT signaling pathway impacting lipid accumulation in RAW264. 7 macrophages.Cytokine. 2019 Jul;119:168-174.  WB ;  Mouse.  
[IF=3.461] Yukiko Yamashita. et al. Discovery of FXR/PPARγ Dual Partial Agonist. BIOORGAN MED CHEM. 2023 Mar;:117238  WB ;  Mouse.  
[IF=3.386] Choung S et al. Treatment with lobeglitazone attenuates hepatic steatosis in diet-induced obese mice.PPAR Res. 2018 Jun 13;2018:4292509.  WB ;  Mouse.  
[IF=3.23] Sarr, Ousseynou, et al. "Low birth weight male guinea pig offspring display increased visceral adiposity in early adulthood." PloS one 9.6 (2014): e98433.  WB ;  Guinea Pig.  
產(chǎn)品類型 磷酸化抗體 
研究領(lǐng)域 腫瘤  細(xì)胞生物  信號(hào)轉(zhuǎn)導(dǎo)  細(xì)胞凋亡  激酶和磷酸酶  表觀遺傳學(xué)  
抗體來(lái)源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human (predicted: Mouse,Rat,Rabbit,Sheep,Cow,Chicken)
產(chǎn)品應(yīng)用 WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 57 kDa
檢測(cè)分子量
細(xì)胞定位 細(xì)胞核 細(xì)胞漿 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273: DK(p-S)PF 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項(xiàng) This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

Function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.

Subunit:
Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with DNTTIP2, MAP2K1/MEK1, PRMT2 and TGFB1I1. Interacts with PDPK1. Interacts with ASXL1 AND ASXL2.

Subcellular Location:
Nucleus. Cytoplasm.

Tissue Specificity:
Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

DISEASE:
Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
P37231

Gene ID:
5468

Database links:

Entrez Gene: 5468?Human

Entrez Gene: 19016?Mouse

Entrez Gene: 25664?Rat

SwissProt: P37231?Human

SwissProt: P37238?Mouse

SwissProt: O88275?Rat

Unigene: 162646?Human

Unigene: 3020?Mouse

Unigene: 23443?Rat



產(chǎn)品圖片
Sample: Lane 1: Human A549 cell lysates Lane 2: Human 293T cell lysates Lane 3: Human HepG2 cell lysates Primary: Anti-Phospho-PPAR Gamma (ser273) (bs-4888R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 57 kDa Observed band size: 57 kDa
phosphopeptide non phosphopeptide
版權(quán)所有 2004-2026 a6308.cn 北京博奧森生物技術(shù)有限公司
通過(guò)國(guó)際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書(shū)編號(hào): 00124Q34771R2M/1100
通過(guò)國(guó)際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書(shū)編號(hào): CQC24QY10047R0M/1100
京ICP備05066980號(hào)-1         京公網(wǎng)安備110107000727號(hào)
国产萌白酱在线一区二区 | 亚洲欧美乱日韩乱国产 | 人妻内射一区二区在线视频 | 午夜国产精品免费观看 | 亚洲精品国品乱码久久久久 | 国产日韓无码一区二区三区久久区 | 国产福利萌白酱白色旗袍 | 麻豆精品传媒一二三区 | 亚洲高清在线精品一区 | BWBWWBWWW高潮| 久久aa毛片免费播放嗯啊 | 亚洲精品熟女国产老熟女 | WWW国产精品内射老师 | 久久人人做人人爽久久99国产乱子伦精品免 | 免费麻豆国产黄网站在线观看 | 国产毛片久久久久久国产毛片 | 久久国产精品高清一区二区三区 | 蜜桃精品免费久久久久影院 | 麻豆精品无码国产在线 | 嫩交18xxxx| 欧美四虏免费一级成人片 | 久久久精品无码一二三区 | 岛国搬运工www啪欧美 | √8天堂资源地址中文在线 欧美精品成人一区二区在线观看 | 亚洲高清成人AV电影网站 | 亚洲综合精品一二三区在线 | 国产精品久久久久无毒 | 亚洲中文无码永久免费 | 中文字幕在线免费观看视频 | 国产91色在线综合亚洲 | 亚洲最大在线视频 | 狠狠躁日日躁夜夜躁2022麻豆 | 性一交一无一伦一精一爆 | 久久另类精品欧美日韩高清精品不卡 | 国产va免费精品高清在线 | 欧美日韩人妻精品一区在线 | 二级毛片在线观看 | 欧美自拍经典综合一区 | 欧美日韩国产一区二区三区地区 | 亚洲一区二区三区高清网 | 国产午夜亚洲精品国产 |